LEF1 in androgen-lndependent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3332-3338

  Li, Yirong ^a   Wang, Longgui ^a   Zhang, Miao ^a   Melamed, Jonathan ^a   Liu, Xiaomei ^a   Reiter, Robert ^c   Wei, Jianjun ^a   Peng, Yi ^a   Zou, Xuanyi ^a   Pellicer, Angel ^a   Garabedian, Michael J ^b   Ferrari, Anna ^a   Lee, Peng ^a,d  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; LYMPHOID ENHANCER FACTOR 1; TUMOR MARKER; LEF1 PROTEIN, HUMAN; MESSENGER RNA;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL STRAIN LNCAP; CELL STRAIN LNCAP AI; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GEL; GEL SHIFT ASSAY; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; BIOSYNTHESIS; CELL GROWTH; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MALE; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER;

EID: 65949084273     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3380     Document Type: Article

References (52)

1. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-in dependent prostate cancer. Clin. Cancer Res 2006; 12: 1665-71.
2. Taplin ME, Bubley GJ, Shuster TD. et al. Mutation of the androgen-reeeptor gene in metastatic androgen-independent prostate cancer. N Engl J. Med 1995; 332: 1393-8.
3. Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin. Pract Oncol 2007; 4: 236-44. (Pubitemid 46510533)
4. Koivisto P, Kononen J, Palmberg C. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-9. (Pubitemid 27036612)
5. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella KE, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550-5. (Pubitemid 32694958)
6. Visakorpi T, Hyytinen E, Koivisto P. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6.
7. Newmark JR, Hardy DO, Tonb DC. et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A 1992; 89: 6319-23.
8. Gaddipati JP, McEeod DG, Heidenberg HB. et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994; 54: 2861-4. (Pubitemid 24187763)
9. Xing RH, Rabbani SA, Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo. Endocrinology 1999; 140: 4056-64. (Pubitemid 30647101)
10. Iguchi K, Ito M, Usui S, Mizokami A, Namiki M, Hirano K. Downregulation of thymosin β4 expression by androgen in prostate cancer LNCaP cells. J. Androl 2008; 29: 207-12.
11. Jagla M, Feve M, Kessler P. et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007; 148: 4334-43. (Pubitemid 47295699)
12. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen receptor and invasion in prostate cancer. Cancer Res 2008; 68: 1128-35.
13. Takane KK, McPhaul MJ, Functional analysis of the human androgen receptor promoter. Mol. Cell Endocrinol. 1996; 119: 983-93. (Pubitemid 26181418)
14. Mizokami A, Chang C. Induction of translation by the 5'-untranslated region of human androgen receptor rnRNA. J. Biol. Chem 1994; 269: 25655-9. (Pubitemid 24336260)
15. Wang EG, Johnson EM, Kinoshita Y. et al. Androgen receptor overexpression in prostate cancer linked to Pur α loss from a novel repressor complex. Cancer Res 2008; 68: 2678-88.
16. Gioeli D, Mandell JW, Petroni GR, Frierson HE, Jr., Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-84. (Pubitemid 29048852)
17. Yoshida RA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999; 59: 5483-7. (Pubitemid 29526462)
18. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J. Biol. Chem 1999; 274: 7777-33. (Pubitemid 129518166)
19. Hobisch A, Eder IE, Putz T. et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58: 4640-5. (Pubitemid 28480629)
20. Matsuda T, Junicho A, Yamamoto T. et al. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 2001; 83: 179-87. (Pubitemid 32912555)
21. Signoretti S, Montironi R, Manola J. et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst 2000; 92: 1918-25. (Pubitemid 32036922)
22. Shi Y, Brands FH, Chatterjee S. et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J. Urol 2001; 166: 1514-9. (Pubitemid 32862230)
23. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5: 280-5. (Pubitemid 29124362)
24. Wen Y, Hu MC, Makino K. et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 6841-5. (Pubitemid 32059149)
25. Yang X, Chen MW, Terry S. et al. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 2006; 25: 3436-44. (Pubitemid 43877046)
26. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta 1999; 1424: M23-37. (Pubitemid 29488713)
27. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-51. (Pubitemid 30639518)
28. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J. Cancer Res Clin. Oncol 2003; 129: 199-221. (Pubitemid 36713796)
29. Nusse R. Wnt signaling in disease and in development. Cell Res 2005; 15: 28-32. (Pubitemid 41653961)
30. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-50. (Pubitemid 40558990)
31. Yardy GW, Brewster SF. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 119-26. (Pubitemid 43118074)
32. Chen CD, Welsbie DS, Tran C. et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9. (Pubitemid 38524696)
33. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45. (Pubitemid 33741879)
34. Gregory CW, He B, Johnson RT. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-9. (Pubitemid 32685750)
35. Wang EG, Ossowski E, Ferrari AC. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 2001; 61: 7544-51. (Pubitemid 32995046)
36. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54: 1566-73. (Pubitemid 24106424)
37. Soto AM, Lin TM, Sakabe K, Olea N. Damassa DA, Sonnenschein C. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgenmediated proliferative response. Oncol Res 1995; 7: 545-58. (Pubitemid 26075387)
38. Gao M, Ossowski E, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J. Cell Physiol 1999; 179: 336-46. (Pubitemid 29203158)
39. Wang EG, Ossowski E, Ferrari AC. Androgen receptor level controlled by α suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 2004; 23: 5175-84. (Pubitemid 38980350)
40. Eiu XM, Jiang JD, Ferrari AC, Budman DR, Wang LG. Unique induction of p21 (WAF1/CIP1) expression by vinorelbine in androgen-independent prostate cancer cells. Br J. Cancer 2003; 89: 1566-73. (Pubitemid 37386616)
41. Peng Y, Li C, Chen F. et al. Stimulation of prostate growth and invasion by androgen receptor cofactor ARA70β. Am J. Pathol. in press.
42. Gao S, Lee P, Wang H. et al. The androgen receptor directly targets the cellular Fas/FasE-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol. Endocrinol. 2005; 9: 1792-802. (Pubitemid 41007891)
43. Wang LG, Liu XM, Li ZR, Denstman S, Bloch A. Differential binding of nuclear c-ets-1 protein to an intron I fragment of the c-myb gene in growth versus differentiation. Cell Growth Differ 1994; 5: 1243-51. (Pubitemid 24347403)
44. Zhou E, Wu H, Fee P, Wang Z. Roles of the androgen receptor cofactor p44 in the growth of prostate epithelial cells. J. Mol. Endocrinol. 2006; 37: 283-300. (Pubitemid 44615299)
45. Gu Y, Li H, Miki J. et al. Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res 2006; 312: 831-43.
46. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J. Cell Biochem 2006; 99: 402-10. (Pubitemid 44435558)
47. Schweizer L, Rizzo CA, Spires TE. et al. The androgen receptor can signal through Wnt/β catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol. 2008; 9: 4.
48. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/β catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 2005; 26: 898-915. (Pubitemid 41770157)
49. Pawlowski JE, Ertel JR, Allen MP. et al. Eiganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J. Biol. Chem 2002; 277: 20702-10.
50. Truica CI, Byers S, Gelmann EP. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60: 4709-13.
51. Brantjes H, Barker N, van Es J, Clevers H. TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biol. Chem 2002; 383: 255-61. (Pubitemid 34229127)
52. Li Y, Li CX, Ye H. et al. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J. Cell Mol. Med 2008; 12: 2790-8.